Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBagguley, Dominic-
dc.contributor.authorOng, Sean-
dc.contributor.authorButeau, James P-
dc.contributor.authorKoschel, Sam-
dc.contributor.authorDhiantravan, Nattakorn-
dc.contributor.authorHofman, Michael S-
dc.contributor.authorEmmett, Louise-
dc.contributor.authorMurphy, Declan G-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2021-03-16-
dc.date.accessioned2021-03-24T21:39:01Z-
dc.date.available2021-03-24T21:39:01Z-
dc.date.issued2021-03-16-
dc.identifier.citationFuture Oncology 2021; online first: 16 Marchen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26098-
dc.description.abstractProstate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity and specificity over and in combination with other currently employed imaging techniques, such as multiparametric MRI, bone scan, PET and CT. However, the lack of strength and confidence in these studies has meant incorporation of PSMA PET/CT into clinical guidelines and practice has been limited to date. In response, a number of high-quality prospective studies have recently emerged and reflect exciting results seen in preceding publications. Here we recount some of the key earlier publications, report results from the latest studies and look to the future discussing some of the eagerly awaited ongoing clinical trials.en
dc.language.isoeng
dc.subjectPET/CTen
dc.subjectPSMAen
dc.subjectdiagnosisen
dc.subjectimagingen
dc.subjectProstate canceren
dc.subjectstagingen
dc.subjecturologyen
dc.titleThe role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleFuture Oncologyen
dc.identifier.affiliationMolecular Imaging & Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, 3000, Australiaen
dc.identifier.affiliationDepartment of Urology, Royal Melbourne Hospital, Parkville, 3000, Australiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationSt Vincent's Hospital Nuclear Medicine & PET Department, Darlinghurst, 2010, Australiaen
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, 3000, Australiaen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 3000, Australiaen
dc.identifier.affiliationEJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, 3121, Australiaen
dc.identifier.doi10.2217/fon-2020-1293en
dc.type.contentTexten
dc.identifier.orcid0000-0002-2555-9316en
dc.identifier.pubmedid33724868
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Sep 3, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.